Company profile: Vertex Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of small molecule drugs for serious diseases, including cystic fibrosis medicines, and research and development of therapies for sickle cell disease, type 1 diabetes, APOL1-mediated kidney disease, pain management, and beta thalassemia.
Products and services
- Cystic Fibrosis Medicines: Engineers small-molecule medicines for cystic fibrosis, a genetic disease affecting lungs and digestive system, advancing discovery and development of therapies for patients
- Type 1 Diabetes Research: Investigates cellular-level treatments for type 1 diabetes, aiming to develop innovative therapies by studying disease processes at the cellular level
- Sickle Cell Disease Research: Architects research-stage treatments for sickle cell disease, focusing on understanding patient experiences and advancing potential therapies through ongoing research and development
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Vertex Pharmaceuticals
Instil Bio
HQ: United States
Website
- Description: Provider of cell therapy solutions focused on tumor infiltrating lymphocytes (TIL) for the treatment of solid tumor cancers, advancing proprietary manufacturing expertise, technology, and data into clinical trials. Programs include a planned registrational study and a first-in-human next-generation engineered TIL, plus FRα CoStAR, a clinical-stage candidate for non-small cell lung cancer (NSCLC).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Instil Bio company profile →
Stada
HQ: Germany
Website
- Description: Provider of pharmaceuticals and non-prescription consumer health products, operating on three pillars: OTC consumer healthcare, generics, and specialty pharmaceuticals. Sells products in over 120 countries, including acetaminophen, lactulose, Grippostad-C, Vitaprost, Cardiomagnyl, Xefocam Rapid, Aqualor, Edarbi, and Levomekol.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Stada company profile →
LEAF Pharmaceuticals
HQ: United States
Website
- Description: Provider of biotechnology and healthcare products, including investigational anticancer drugs targeting solid tumors (LEAF-1401, LEAF-1701) with preclinical results showing reduced metastatic tumor burden in lung cancer models, superior performance in colorectal models, and minimal myelosuppression and gastrointestinal toxicity, plus LEAF-1404, a complex generic anticancer medicine manufactured under global cGMP.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LEAF Pharmaceuticals company profile →
Valera Pharmaceuticals
HQ: United States
Website
- Description: Provider of specialty pharmaceutical services concentrating on development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Valera Pharmaceuticals company profile →
VivaBioCell
HQ: Italy
Website
- Description: Provider of innovative products leveraging proprietary cell culture and tissue engineering technologies for early diagnosis of autoimmune diseases (e.g., scleroderma, graft-versus-host disease) and treatment of oro-dental and maxillo-facial defects.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full VivaBioCell company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Vertex Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Vertex Pharmaceuticals
2.2 - Growth funds investing in similar companies to Vertex Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Vertex Pharmaceuticals
4.2 - Public trading comparable groups for Vertex Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →